Barratt Developments Creates Master Developer JV for U.K. Housing Projects
By Anthony O. Goriainoff
Barratt Developments said it was launching a joint venture aimed at creating residential-led developments for 1,000 to 10,000 homes in the U.K.
The London-listed house builder said on Monday that it was joining government agency Homes England and Lloyds Banking Group to create the MADE Partnership, a long-term master developer proposal initially backed by up to 150 million pounds ($197 million) in equity funding.
The company said MADE's potential development opportunities include large brownfield developments--sites previously developed for industrial or commercial purposes--as well as new garden village style communities.
"The landmark new partnership...will support our commitment to ramp up housing supply and boost economic growth by developing more large-scale, attractive and sustainable places across the country with the homes, jobs and infrastructure that communities need to thrive," Housing and Planning Minister Matthew Pennycook said.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
September 09, 2024 02:42 ET (06:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks